X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs PIRAMAL ENTERPRISES - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON PIRAMAL ENTERPRISES BIOCON /
PIRAMAL ENTERPRISES
 
P/E (TTM) x 38.1 30.8 123.7% View Chart
P/BV x 6.0 1.4 421.8% View Chart
Dividend Yield % 0.2 1.1 16.8%  

Financials

 BIOCON    PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    BIOCON
Mar-18
PIRAMAL ENTERPRISES
Mar-18
BIOCON /
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,1883,083 38.5%   
Low Rs3051,902 16.0%   
Sales per share (Unadj.) Rs68.7589.7 11.7%  
Earnings per share (Unadj.) Rs7.6284.0 2.7%  
Cash flow per share (Unadj.) Rs14.0310.5 4.5%  
Dividends per share (Unadj.) Rs1.0025.00 4.0%  
Dividend yield (eoy) %0.11.0 13.4%  
Book value per share (Unadj.) Rs86.31,467.0 5.9%  
Shares outstanding (eoy) m600.00180.27 332.8%   
Bonus/Rights/Conversions ISIS-  
Price / Sales ratio x10.94.2 257.0%   
Avg P/E ratio x98.98.8 1,126.5%  
P/CF ratio (eoy) x53.48.0 665.7%  
Price / Book Value ratio x8.61.7 508.8%  
Dividend payout %13.28.8 150.4%   
Avg Mkt Cap Rs m447,900449,332 99.7%   
No. of employees `0006.16.8 89.9%   
Total wages/salary Rs m9,31119,881 46.8%   
Avg. sales/employee Rs Th6,705.815,535.6 43.2%   
Avg. wages/employee Rs Th1,514.22,905.4 52.1%   
Avg. net profit/employee Rs Th736.97,482.5 9.8%   
INCOME DATA
Net Sales Rs m41,234106,310 38.8%  
Other income Rs m2,0622,595 79.5%   
Total revenues Rs m43,296108,906 39.8%   
Gross profit Rs m8,29151,599 16.1%  
Depreciation Rs m3,8514,773 80.7%   
Interest Rs m61529,783 2.1%   
Profit before tax Rs m5,88719,638 30.0%   
Minority Interest Rs m2132,801 7.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569-28,764 -5.5%   
Profit after tax Rs m4,53151,203 8.8%  
Gross profit margin %20.148.5 41.4%  
Effective tax rate %26.7-146.5 -18.2%   
Net profit margin %11.048.2 22.8%  
BALANCE SHEET DATA
Current assets Rs m41,486118,154 35.1%   
Current liabilities Rs m21,413462,260 4.6%   
Net working cap to sales %48.7-323.7 -15.0%  
Current ratio x1.90.3 758.0%  
Inventory Days Days6427 240.7%  
Debtors Days Days9447 202.4%  
Net fixed assets Rs m50,661113,727 44.5%   
Share capital Rs m3,000361 832.2%   
"Free" reserves Rs m48,808264,093 18.5%   
Net worth Rs m51,808264,454 19.6%   
Long term debt Rs m17,898242,206 7.4%   
Total assets Rs m99,897726,834 13.7%  
Interest coverage x10.61.7 637.1%   
Debt to equity ratio x0.30.9 37.7%  
Sales to assets ratio x0.40.1 282.2%   
Return on assets %5.211.1 46.2%  
Return on equity %8.719.4 45.2%  
Return on capital %9.610.3 93.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05815,110 79.8%   
Fx outflow Rs m7,3484,298 171.0%   
Net fx Rs m4,71010,813 43.6%   
CASH FLOW
From Operations Rs m6,621-159,666 -4.1%  
From Investments Rs m-6,840-17,677 38.7%  
From Financial Activity Rs m-2,397186,503 -1.3%  
Net Cashflow Rs m-2,6129,364 -27.9%  

Share Holding

Indian Promoters % 40.4 52.9 76.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 4.0 210.0%  
FIIs % 10.7 26.6 40.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 16.5 120.6%  
Shareholders   109,995 93,274 117.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  PLETHICO PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 140 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets ended their day on a positive note today ahead of counting of Lok Sabha Election 2019 to be done tomorrow.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 22, 2019 (Close)

TRACK BIOCON

BIOCON - ALEMBIC PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS